An expert discusses how the treatment landscape for lower-risk MDS has evolved with multiple new options including luspatercept, imetelstat, and lenalidomide based on specific patient characteristics ...

Researchers are developing AI programmes to make doping detection more effective, faster, and cheaper. How do these systems ...

Geron gets its first product approval, Rytelo for myelodysplastic syndromes, which also becomes the first telomerase inhibitor to be cleared for marketing.

Reblozyl was found to be superior to standard ESA therapy with Amgen and Johnson & Johnson's Epogen/Procrit (epoetin alfa) at achieving those objectives, with almost 59% of patients on BMS' drug ...